The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia.
 
Joseph Scandura
Stock and Other Ownership Interests - Cellectis; Protagonist Therapeutics; Scholar Rock
Consulting or Advisory Role - Abbvie; CTI BioPharma Corp; MorphoSys; PharmaEssentia; SDP Oncology
 
Aaron Thomas Gerds
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; CTI; GlaxoSmithKline/Sierra Oncology; Imago Pharma; Kartos Therapeutics; MorphoSys; Pharmaessentia; Rain Therapeutics
Research Funding - Celgene; CTI; Gilead Sciences; Incyte; Pfizer; Roche/Genentech
 
Ellen K. Ritchie
Consulting or Advisory Role - bristol myers squibb; Celgene; Incyte; Novartis; Pfizer
Speakers' Bureau - Celgene; Incyte
Research Funding - Astellas Pharma (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Xulong Wang
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Steve Kye
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Abbvie; Karyopharm Therapeutics; Pfizer; Xencor
Patents, Royalties, Other Intellectual Property - Abbvie
 
Raajit Rampal
Honoraria - Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Disc Medicine; Galecto; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia; Promedior; SERVIER; Sierra Oncology; Stemline Therapeutics; Sunimoto Dainippon; Zentalis
Research Funding - Constellation Pharmaceuticals; Ryvu Therapeutics; Stemline Therapeutics; Zentalis
Travel, Accommodations, Expenses - Incyte; Sierra Oncology